Related Experiment Video
Updated: Jul 11, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60
Florent Grange1, Marie Beylot-Barry, Phillipe Courville
1Department of Dermatology, Hôpital Robert Debré, Avenue du Général Koenig, Reims 51100, France. fgrange@chu-reims.fr
Archives of Dermatology
|September 19, 2007
Summary
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT) has a poor prognosis, especially with leg involvement and multiple lesions. Combination therapy with anthracyclines and rituximab may improve outcomes for this rare lymphoma.
Area of Science:
- Dermatology
- Hematology
- Oncology
Background:
- Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT) is a distinct entity.
- Recent classifications highlight its unique characteristics.
Purpose of the Study:
- To define clinicopathologic features of PCLBCL LT.
- To identify prognostic factors for disease-specific survival.
Main Methods:
- Retrospective multicenter study of 60 PCLBCL LT patients.
- Data collected included demographics, clinical presentation, therapy, and molecular markers.
- Prognostic factors analyzed using Cox proportional hazards model.
Main Results:
- PCLBCL LT predominantly affects the leg (72%), occurs in older patients (mean age 76), and shows high Bcl-2 expression (85%).
- Five-year disease-specific survival was 41%, with leg location and multiple lesions predicting mortality.
- Recent anthracycline/rituximab combinations showed a favorable short-term outcome.
Conclusions:
- PCLBCL LT is an aggressive lymphoma with a poor prognosis, particularly for patients with leg lesions.
- Combination chemotherapy including anthracyclines and rituximab may offer improved survival, even in elderly patients.
